Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present AzurRx BioPharma, Inc. (NASDAQ: AZRX).

Full DD Report for AZRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: AZRX)

Premarket Losers as of 9:05 am (5/1/2018)
IVAC   -24%  on Q1 earnings . More news on: Intevac, Inc., CommScope Holding Company Inc., Cognex Corporation, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 01 2018 09:13
AzurRx BioPharma Announces Pricing of $10.4 Million Public Offering of Common Stock
BROOKLYN, N.Y., May 01, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma (NASDAQ:AZRX), (“AzurRx” or the “Company”), today announced the pricing of an underwritten public offering of 4,160,000 shares of its common stock at an offering price of $2.50 per share. The gross...
Source: GlobeNewswire
Date: May, 01 2018 09:10
AzurRx BioPharma Announces Proposed Public Offering of Common Stock
BROOKLYN, N.Y., April 30, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma (NASDAQ:AZRX), (“AzurRx” or the “Company”), announced today that it intends to offer and sell shares of its common stock in an underwritten public offering.  AzurRx intends to use the net pr...
Source: GlobeNewswire
Date: April, 30 2018 16:15
AzurRx down 5% on interim mid-stage data on lead candidate in EPI
Thinly traded nano cap AzurRx BioPharma ( AZRX -5.4% ) slips on light volume on the heels of its announcement of preliminary data from an open-label Phase 2a clinical trial assessing MS1819-SD in exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis. More news on: Azur...
Source: SeekingAlpha
Date: April, 23 2018 12:20
AzurRx BioPharma and Mayoly-Spindler Announce Additional Positive Interim Data for MS1819-SD Phase II in Exocrine Pancreatic Insufficiency (EPI)
BROOKLYN, N.Y., April 23, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), today provided an update on the first nine treated patients in its ongoing Phase IIa trial of MS1819-SD, a recombinant lipase, for the treatment of...
Source: GlobeNewswire
Date: April, 23 2018 08:45
NetworkNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Releases Positive AZX1103 Preclinical Results
AzurRx BioPharma Inc. (NASDAQ: AZRX) today released positive results for preclinical testing of its AZX1103 product, a b-lactamase enzyme combination treatment designed to prevent hospital-acquired gastro-intestinal infections for patients receiving antibiotics in the hospital setting. As stat...
Source: NetworkNewsWire
Date: April, 18 2018 09:30
AzurRx BioPharma Announces Positive Preclinical Data with AZX1103
Company is developing AZX1103 for the prevention of nosocomial infections induced by administration of several classes of antibiotics AZX1103 shown to be safe and biologically active in a well-established pre-clinical model  BROOKLYN, N.Y., April 18, 2018 (GLOBE NEWSWIRE) -- AzurR...
Source: GlobeNewswire
Date: April, 18 2018 07:45
Stock Market Manager Announces the Hosting of Research Coverage of AzurRx, Biopharma, Inc. (NASDAQ: AZRX) by Trickle Research LLC
CLEARWATER, FL / ACCESSWIRE / March 2, 2018 / The AzurRx Biopharma, Inc. (NASDAQ: AZRX) research report is available on Stock Market Manager ( smm.global ): Research Report Here>> About AzurRx, Biopharma, Inc. AzurRx BioPharma is a development stage biopharmaceutical c...
Source: ACCESSWIRE IA
Date: March, 02 2018 09:00
AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th)
BROOKLYN, N.Y., Feb. 28, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company will be...
Source: GlobeNewswire
Date: February, 28 2018 08:30
AzurRX Biopharma (AZRX) Presents At BIO CEO & Investor Conference - Slideshow
The following slide deck was published by AzurRX Biopharma in conjunction with this Read more ...
Source: SeekingAlpha
Date: February, 13 2018 13:58

 


About AzurRx BioPharma, Inc. (NASDAQ: AZRX)

Logo for AzurRx BioPharma, Inc. (NASDAQ: AZRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: AZRX)

      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 11 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 11 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 11 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 11 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 04 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: May, 02 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: May, 02 2018
      Registration of up to an additional 20% of securities for any offering registered on a S-3
      Filing Type: S-3MEFFiling Source: edgar
      Filing Date: May, 01 2018
      Registration of up to an additional 20% of securities for any offering registered on a S-3
      Filing Type: S-3MEFFiling Source: edgar
      Filing Date: May, 01 2018

       

       


      Daily Technical Chart for (NASDAQ: AZRX)

      Daily Technical Chart for (NASDAQ: AZRX)


      Stay tuned for daily updates and more on (NASDAQ: AZRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: AZRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      Monsta Trader
      @MonstaTrader

       

       


      Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AZRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of AZRX and does not buy, sell, or trade any shares of AZRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/